Biotech IPOs, FDA-Stealth & patent threat — a BioCentury podcast

Signs of life in the biotech IPO market

There’s been a rare IPO filing on NASDAQ as LB Pharmaceuticals Inc. looks to test the market during a year that has seen little activity among U.S. biotechs even as green shoots continue to appear on the Hong Kong stock exchange. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for biotech IPOs on NASDAQ and in Hong Kong. 

The analysts then assess FDA’s about-face on Stealth BioTherapeutics Inc.’s Barth syndrome therapy, putting the decision in the context of a changing regulatory agency; and a BioCentury Guest Commentary that argues that the university-industry engine that drives U.S. innovation is under attack.

Also mentioned on this week’s podcast: BioCentury’s 33rd Back to School package, which reimagines FDA; the upcoming 12th China Healthcare Summit in Shanghai; the evolution of dealmaking in China; and Annalisa Jenkins’ take on MHRA and the U.K. biotech ecosystem on The BioCentury Show.

Advanced rates for the China Healthcare Summit end Friday; register now as a delegate or apply to join the Presenting Company Class of 2025.